Azienda Ospedaliera Papardo

At Azienda Ospedaliera Papardo in Messina, research in Hemic and Lymphatic Diseases focuses on improving care for leukemias, lymphomas, and multiple myeloma. These studies are designed to test new treatment approaches, refine disease control, and deepen understanding of response in both newly diagnosed and relapsed disease.

• Chronic lymphocytic leukemia and small lymphocytic lymphoma studies exploring better first-line and subsequent treatment strategies
• Multiple myeloma research evaluating newer combinations and treatment effectiveness in patients who are not eligible for transplant or who have relapsed disease
• Acute leukemias, including Philadelphia chromosome-positive acute lymphoblastic leukemia and acute myeloid leukemia, with a focus on more effective disease control and deeper remission
• Lymphoma studies in follicular lymphoma, Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and ocular adnexal marginal zone lymphoma

This program reflects a strong interest in hematologic oncology, with trials aimed at improving survival, reducing residual disease, and identifying more precise treatment options.

A major part of the clinical trial portfolio at this hospital is dedicated to neoplasms, especially breast cancer across early, locally advanced, metastatic, and brain-metastatic settings. The research is centered on evaluating new therapies, improving outcomes after standard treatment, and addressing disease that has become resistant to prior hormonal or targeted approaches.

• Hormone receptor-positive, HER2-negative breast cancer studies in advanced and metastatic disease
• HER2-positive breast cancer and HER2-low breast cancer trials focused on treatment effectiveness
• Triple-negative breast cancer research in residual disease after initial therapy
• Studies involving brain metastases from breast cancer to improve control of advanced disease

The breast cancer program includes work on both targeted and immunotherapy-based strategies, with the goal of expanding options for patients whose disease has progressed after standard care.

The site also conducts clinical trials in Respiratory Tract Diseases, especially non-small cell lung cancer in locally advanced, unresectable, metastatic, and post-surgical settings. These studies aim to improve survival, strengthen maintenance treatment, and assess the value of new immunotherapy and targeted therapy combinations.

• Non-small cell lung cancer trials testing new treatment combinations and maintenance strategies
• Research in stage III unresectable disease focused on extending survival after chemoradiotherapy
• Studies in PD-L1-selected and advanced lung cancer populations to compare treatment effectiveness

This work highlights an ongoing effort to improve outcomes in lung cancer through better sequencing, consolidation, and long-term disease control.

A further group of trials at UOC Oncologia medica addresses other solid tumors and areas where treatment is guided by molecular features. These studies include colorectal cancer and selected advanced cancers, with an emphasis on comparing treatment strategies, optimizing sequencing, and tailoring therapy to tumor biology.

• Metastatic colorectal cancer trials comparing treatment sequences and first-line options
• Research in molecularly selected cancer populations using biomarkers such as RAS and BRAF
• Studies aimed at improving treatment choice in advanced solid tumors through more personalized approaches

Overall, these trials show a broad oncology research profile that combines standard cancer care with newer targeted and biomarker-informed strategies.